FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia
Running, not enrolling · Phase 2
Conditions studied: Acute Myeloid Leukemia
In brief
This phase II trial studies fluorothymidine F 18 (FLT) positron emission tomography (PET)/computed tomography (CT) in measuring response in patients with previously untreated acute myeloid leukemia. FLT is a radioactive substance that may "light up" where cancer is in the body. FLT is injected into the blood and builds up in cells that are dividing, including cancer cells. Diagnostic procedures, such as PET/CT, may help measure a patient's response to earlier treatment.
Key facts
- Study ID
- NCT02392429
- Run by
- National Cancer Institute (NCI)
- People needed
- 87
- Starts
- 2016-04-20
- Expected to finish
- 2027-02-13
- Last updated by the study team
- 2026-05-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 18 years
- Patients must have previously untreated AML and be candidates for intensive induction chemotherapy; patients are allowed to have had prior hydroxyurea
- Patients must not have acute promyelocytic leukemia (APL) and must not have evidence of t(15;17)(q22;q21)
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 (restricted to ECOG performance status [PS] 0-2 if age > 70 years)
- Patients must have left ventricular ejection fraction (LVEF) > 45% or within institutional normal limits
- Patients must be able to lie still for a 1.5 hour PET scan
- Patient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-fluorothymidine
- Patient must NOT weigh more than the maximum weight limit for the PET/CT table for the scanner(s) to be used at each center
- The patient is participating in the trial at an institution which has agreed to perform the imaging research studies, completed the ECOG-American College of Radiology Imaging Network (ACRIN) defined scanner qualification procedures and received ECOG-ACRIN approval as outlined
- Women must not be pregnant or breast-feeding; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
Where it is running
- Mayo Clinic in Rochester — Rochester, Minnesota, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- Mount Sinai Hospital — New York, New York, United States
- UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina, United States
- University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma, United States
- University of Pennsylvania/Abramson Cancer Center — Philadelphia, Pennsylvania, United States
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee, United States
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas, United States
- Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah, United States
- University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.